Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats

Kidney International

Volumn 84, Issue 5, 2013, Pages 931-939

  Ali, Quaisar ^a,b   Wu, Yonnie ^b   Hussain, Tahir ^b  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

CGP42112A; obesity; RAS; renin AT2 receptor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; CANDESARTAN; CELL PROTEIN; MAS RECEPTOR; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; RENIN; SODIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENZYME ACTIVITY; IN VITRO STUDY; KIDNEY FUNCTION; MALE; NATRIURESIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; RAT; SODIUM URINE LEVEL;

ANGIOTENSIN I; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CELL LINE; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY CORTEX; MALE; NATRIURESIS; OBESITY; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RATS; RATS, ZUCKER; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, G-PROTEIN-COUPLED; RENIN; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS; UP-REGULATION;

EID: 84888375977     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.193     Document Type: Article

References (71)

1. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-14843.
2. Rice GI, Thomas DA, Grant PJ et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 2004; 383: 45-51.
3. de Gasparo M, Catt KJ, Inagami T et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
4. Akishita M, Ito M, Lehtonen JY et al. Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. J Clin Invest 1999; 103: 63-71.
5. Masaki H, Kurihara T, Yamaki A et al. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptormediated pressor and chronotropic effects. J Clin Invest 1998; 101: 527-535.
6. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998; 83: 1182-1191.
7. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996; 93: 156-160.
8. Meffert S, Stoll M, Steckelings UM et al. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrionol 1996; 122: 59-67.
9. Hakam AC, Hussain T. Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats. Hypertension 2005; 45: 270-275.
10. Hakam AC, Siddiqui AH, Hussain T. Renal angiotensin II AT2 receptors promote natriuresis in streptozotocin-induced diabetic rats. Am J Physiol Renal Physiol 2006; 290: F503-F508.
11. Hilliard LM, Jones ES, Steckelings UM et al. Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension. Hypertension 2012; 59: 409-414.
12. Ali Q, Hussain T. AT(2) receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats. Hypertens Res 2012; 35: 654-660.
13. Carey RM. Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 2005; 14: 67-71.
14. Duke LM, Evans RG, Widdop RE. AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 288: H2289-H2297.
15. Gao J, Zhang H, Le KD et al. Activation of central angiotensin type 2 receptors suppresses norepinephrine excretion and blood pressure in conscious rats. Am J Hypertens 2011; 24: 724-730.
16. Siddiqui AH, Ali Q, Hussain T. Protective role of angiotensin II subtype 2 receptor in blood pressure increase in obese Zucker rats. Hypertension 2009; 53: 256-261.
17. Ferrario CM, Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol 2010; 298: F1297-F1305.
18. Caruso-Neves C, Lara LS, Rangel LB et al. Angiotensin-(1-7) modulates the ouabain-insensitive Na\+-ATPase activity from basolateral membrane of the proximal tubule. Biochim Biophys Acta 2000; 1467: 189-197.
19. De Souza AM, Lopes AG, Pizzino CP et al. Angiotensin II and angiotensin-(1-7) inhibit the inner cortex Na\+-ATPase activity through AT2 receptor. Regul Pept 2004; 120: 167-175.
20. Santos RA, Simoes e Silva AC, Maric C et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263.
21. Garcia NH, Garvin JL. Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol 1994; 5: 1133-1138.
22. Zimpelmann J, Burns KD. Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol 2009; 296: F337-F346.
23. Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin IIstimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 2006; 69: 2212-2218.
24. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 1993; 52: 1461-1480.
25. Hall JE, Jones DW, Kuo JJ et al. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep 2003; 5: 386-392.
26. Alonso-Galicia M, Brands MW, Zappe DH et al. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 1996; 28: 1047-1054.
27. Shah S, Hussain T. Enhanced angiotensin II-induced activation of Na\+, K\+-ATPase in the proximal tubules of obese Zucker rats. Clin Exp Hypertens 2006; 28: 29-40.
28. Becker M, Umrani D, Lokhandwala MF et al. Increased renal angiotensin II AT1 receptor function in obese Zucker rat. Clin Exp Hypertens 2003; 25: 35-47.
29. Hakam AC, Hussain T. Angiotensin II type 2 receptor agonist directly inhibits proximal tubule sodium pump activity in obese but not in lean Zucker rats. Hypertension 2006; 47: 1117-1124.
30. Sabuhi R, Ali Q, Asghar M et al. Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am J Physiol Renal Physiol 2011; 300: F700-F706.
31. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Cin Pract Nephrol 2006; 2: 582-593.
32. Kaneto H, Katakami N, Matsuhisa M et al. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm 2010; 2010: 453892.
33. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999; 33: 613-621.
34. Ichihara A, Hayashi M, Hirota N et al. Angiotensin II type 2 receptor inhibits prorenin processing in juxtaglomerular cells. Hypertens Res 2003; 26: 915-921.
35. Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 2008; 295: H2373-H2379.
36. Morrison RG, Mills C, Moran AL et al. A moderately high fat diet promotes salt-sensitive hypertension in obese zucker rats by impairing nitric oxide production. Clin Exp Hypertens 2007; 29: 369-381.
37. Tallam LS, Jandhyala BS. Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin-converting enzyme inhibition in obese Zucker rats. Clin Exp Pharmacol Physiol 2001; 28: 433-440.
38. Ferrario CM, Chappell MC, Tallant EA et al. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30: 535-541.
39. Pinheiro SV, Simoes ESAC. Angiotensin converting enzyme 2, Angiotensin-(1-7), and receptor MAS axis in the kidney. Int J Hypertens 2012; 2012: 414128.
40. Santos RA, Ferreira AJ, Pinheiro SV et al. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 2005; 14: 1019-1031.
41. Gupte M, Thatcher SE, Boustany-Kari CM et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler Thromb Vasc Biol 2012; 32: 1392-1399.
42. Porsti I, Bara AT, Busse R et al. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 1994; 111: 652-654.
43. Grobe JL, Mecca AP, Mao H et al. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006; 290: H2417-H2423.
44. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005; 289: H2281-H2290.
45. DelliPizzi AM, Hilchey SD, Bell-Quilley CP. Natriuretic action of angiotensin(1-7). Br J Pharmacol 1994; 111: 1-3.
46. Cerrato BD, Frasch AP, Nakagawa P et al. Angiotensin-(1-7) upregulates central nitric oxide synthase in spontaneously hypertensive rats. Brain Res 2012; 1453: 1-7.
47. Nagata S, Kato J, Sasaki K et al. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 2006; 350: 1026-1031.
48. AbdAlla S, Lother H, Abdel-tawab AM et al. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001; 276: 39721-39726.
49. Xu ZG, Lanting L, Vaziri ND et al. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation 2005; 111: 1962-1969.
50. Yang J, Chen C, Ren H et al. Angiotensin II AT2 receptor decreases AT1 receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. J Hypertens 2012; 30: 1176-1184.
51. Siragy HM, Inagami T, Carey RM. NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1461-R1467.
52. Sharma R, Sharma M, Reddy S et al. Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes. Front Biosci 2006; 11: 968-976.
53. Choi JW, Pai SH, Kim SK et al. Increases in nitric oxide concentrations correlate strongly with body fat in obese humans. Clin Chem 2001; 47: 1106-1109.
54. Tsutsumi Y, Matsubara H, Masaki H et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-935.
55. Hein L, Meinel L, Pratt RE et al. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 1997; 11: 1266-1277.
56. Hunyady L. Molecular mechanisms of angiotensin II receptor internalization. J Am Soc Nephrol 1999; 10(Suppl 11): S47-S56.
57. Hakam AC, Hussain T. Angiotensin II AT2 receptors inhibit proximal tubular Na\+-K\+-ATPase activity via a NO/cGMP-dependent pathway. Am J Physiol Renal Physiol 2006; 290: F1430-F1436.
58. Chagnac A, Weinstein T, Korzets A et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278: F817-F822.
59. Herder C, Schneitler S, Rathmann W et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 2007; 92: 4569-4574.
60. Ferder L, Inserra F, Martinez-Maldonado M. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress Curr Hypertens Rep 2006; 8: 191-198.
61. Samuel P, Ali Q, Sabuhi R et al. High Na-intake increases renal angiotensinII levels and reduces the expression of ACE2-AT2R-MasR axis in obese Zucker rats. Am J Physiol Renal Physiol 2012; 303: F412-F419.
62. Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney. ScientificWorldJournal 2009; 9: 522-535.
63. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1-7): in vivo and in vitro studies. Am J Physiol 1996; 270: F141-F147.
64. Dharmani M, Mustafa MR, Achike FI et al. Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. Eur J Pharmacol 2007; 561: 144-150.
65. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005; 45: 960-966.
66. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998; 31: 356-361.
67. Fraser TB, Turner SW, Mangos GJ et al. Comparison of telemetric and tail-cuff blood pressure monitoring in adrenocorticotrophic hormone-treated rats. Clin Exp Pharmacol Physiol 2001; 28: 831-835.
68. Feng M, Whitesall S, Zhang Y et al. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008; 21: 1288-1291.
69. Qi Z, Whitt I, Mehta A et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004; 286: F590-F596.
70. Ali Q, Sabuhi R, Hussain T. High glucose up-regulates angiotensin II subtype 2 receptors via interferon regulatory factor-1 in proximal tubule epithelial cells. Mol Cell Biochem 2010; 344: 65-71.
71. Satou R, Gonzalez-Villalobos RA, Miyata K et al. Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells. Am J Physiol Renal Physiol 2008; 295: F283-F289.